Abstract
Abnormally low intramuscular glutamate and glutathione (GSH) levels and/or a decreased muscular uptake of glutamate by the skeletal muscle tissue have previously been found in malignant diseases and simian immunodeficiency virus (SIV) infection and may contribute to the development of cachexia. We tested the hypothesis that an impaired mitochondrial energy metabolism may compromise the Na+-dependent glutamate transport. A randomized double-blind clinical trial was designed to study the effects of L -carnitine, i.e. an agent known to enhance mitochondrial integrity and function, on the glutamate transport and plasma glutamate level of cancer patients. The effect of carnitine on the intramuscular glutamate and GSH levels was examined in complementary experiments with tumour-bearing mice. In the mice, L -carnitine treatment ameliorated indeed the tumour-induced decrease in muscular glutamate and GSH levels and the increase in plasma glutamate levels. The carnitine-treated group in the randomized clinical study showed also a significant decrease in the plasma glutamate levels but only a moderate and statistically not significant increase in the relative glutamate uptake in the lower extremities. Further studies may be warranted to determine the effect of L -carnitine on the intramuscular GSH levels in cancer patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bremer J (1983) Carnitine – metabolism and functions. Physiol Rev 63: 1420–1480
Brennan MF (1977) Uncomplicated starvation versus cancer cachexia. Cancer Res 37: 2359–2364
Dodson WL, Sachan DS, Krauss S and Hanna W (1989) Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr 8: 133–142
Dröge W, Eck H-P, Betzler M, Schlag P, Drings P and Ebert W (1988 a) Plasma glutamate concentration and lymphocyte activity. J Cancer Clin Oncol 114: 124–128
Dröge W, Eck H-P, Näher H, Pekar U and Daniel V (1988 b) Abnormal amino acid concentrations in the blood of patients with acquired immune deficiency syndrome (AIDS) may contribute to the immunological defect. Biol Chem Hoppe-Seyler 369: 143–148
Eck H-P, Drings P and Dröge W (1989) Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma. J Cancer Clin Oncol 115: 571–574
Eck H-P, Stahl-Hennig C, Hunsmann G and Dröge W (1991) Metabolic disorder as an early consequence of simian immunodeficiency virus infection in rhesus macaques. Lancet 338: 346–347
Fox BA, Spiess PJ, Kasid A, Puri R, Mulé JJ, Weber JS and Rosenberg SA (1990) In vitro and in vivo antitumor properties of a T cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 9: 499–511
Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106: 207–212
Groß A, Hack V, Stahl-Henning C and Dröge W (1996) Elevated hepatic γ-glutamylcysteine synthetase activity and abnormal sulfate levels in liver and muscle tissue may explain abnormal cysteine and glutathione levels in SIV-infected rhesus macaques. AIDS Res Hum Retrovirus 12: 1639–1641
Hack V, Gross A, Kinscherf R, Bockstette M, Fiers W, Berke G and Dröge W (1996 a) Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia. FASEB J 10: 1219–1226
Hack V, Stütz O, Kinscherf R, Schykowski M, Kellerer M, Holm E and Dröge W (1996 b) Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity. J Mol Med 74: 337–343
Hack V, Schmidt D, Breitkreutz R, Stahl-Henning C, Kinscherf R, Taut F, Holm E and Dröge W (1997) Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV/SIV infection, and senescence. FASEB J 11: 84–92
Hagen TM, Ingersoll RT, Wehr CM, Lykkesfeldt J, Vinarsky V, Bartholomew JC, Song M-H and Ames BN (1998) Acetyl- L -carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA 95: 9562–9566
Horn LW (1989) L-Glutamate transport in internally dialysed barnacle muscle fibres. Am J Physiol 257: C442–C450
Kinscherf R, Hack V, Fischbach T, Friedmann B, Weiss C, Edler L, Bärtsch P and Dröge W (1996) Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine. J Mol Med 74: 393–400
Low SY, Rennie MJ and Taylor PM (1994) Sodium-dependent glutamate transport in cultured rat myotubes increases after glutamate deprivation. FASEB J 8: 127–131
McFalls EO, Paulson DJ, Gilbert EF and Shug AL (1986) Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci 38: 497–505
McGarry JD and Foster DW (1976) An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Res 17: 277–281
McGivan JD and Pastor-Anglada M (1994) Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 299: 321–334
Nikula P, Ruohola H, Alhonen-Hongisto L and Janne J (1985) Carnitine prevents the early mitochondrial damage induced by methylglyoxal bis(guanylhydrazone) in L1210 leukemia cells. Biochem J 228: 513–516
Peterson GL (1977) A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem 83: 346–356
Pisters PWT and Pearlstone DB (1993) Protein and amino acid metabolism in cancer cachexia: lnvestigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 30: 223–272
Plaitakis A and Caroscio JT (1987) Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22: 575–579
Rebouche CJ and Paulson DS (1986) Carnitine metabolism and function in humans. Ann Rev Nutr 6: 41–66
Richman PG and Meister A (1975) Regulation of γ-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem 250: 1422–1426
Rössle C, Pichard C, Roulet M, Bergström J and Fürst P (1989) Muscle carnitine pools in cancer patients. Clin Nutr 8: 341–346
Roth E, Funovics J, Mühlbacher F, Schemper M, Mauritz W, Sporn P and Fritsch A (1982) Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr 1: 25–41
Shaw JH and Wolfe RR (1987) Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion and TPN. Surgery 101: 181–186
Striebel J-P, Saeger H-D, Ritz R, Leweling H and Holm E (1986) Aminosäureaufnahme und-abgabe kolorektaler Karzinome des Menschen. Infusionstherupie 13: 92–104
Tayek JA (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Col Nutr 11: 445–456
Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502–522
Wilmore DW and Aulick LH (1978) Metabolic changes in burned patients. Surg Clin N Am 58: 1173–1187
Winter BK, Fiskum G and Gallo LL (1995) Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 72: 1173–1179
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Breitkreutz, R., Babylon, A., Hack, V. et al. Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer 82, 399–403 (2000). https://doi.org/10.1054/bjoc.1999.0933
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0933
Keywords
This article is cited by
-
Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies
European Journal of Nutrition (2013)
-
l ‐carnitine and cancer cachexia: Clinical and experimental aspects
Journal of Cachexia, Sarcopenia and Muscle (2011)
-
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
British Journal of Cancer (2002)